Merck completed its acquisition of Acceleron Pharma for about $11.5 billion, the drugmaker said Nov. 22. Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share ...

(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring ...

It's been an up-and-down kind of year so far for Acceleron Pharma (XLRN +0.00%). In September, the biotech announced disappointing phase 2 results for ACE-083 in treating facioscapulohumeral muscular ...

To say Acceleron has had a roller coaster of a year would be an understatement. The biotech’s pipeline took a hit in September when it canned a phase 2 study of a prospect in a type of muscular ...